Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines

/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX:CSL), today announced that the Biomedical Advanced Research...

Related Keywords

United States ,Australia ,Holly Springs ,Northern Territory ,Hong Kong ,New Jersey ,American ,Marc Lacey ,Maria Tortoreto ,Dave Sehgal ,Prnewswire Seqirus ,American Society Of Gene Cell Therapy ,National Pre ,Pandemic Response Solutions ,Us Department Of Health Human Services ,Centers For Disease ,Us Department Of Health ,Biomedical Advanced Research ,Seqirus United States Inc ,Human Services ,Drug Administration ,World Health Organization ,Us National Influenza Vaccine Modernization Strategy ,Development Authority ,Pandemic Influenza Vaccine Stockpile Program ,Seqirus Inc ,Office Of The ,Public Health Emergency ,Seqirus United Kingdom ,Successful Partnership ,National Notifiable Diseases Surveillance System Modernization Initiative ,Assistant Secretary ,Monovalent Vaccine ,Executive Director ,Utilize Proven ,Promising Platform ,Influenza Vaccine Modernization Strategy ,Seqiru Holly Springs ,Holly Springs Site Head ,National Pre Pandemic Influenza Vaccine Stockpile ,Seqirus United States ,Prescribing Information ,Seqirus United Kingdom Limited ,Give Equivalent Protection ,Much Lower ,American Society ,Health Organization ,Accessed October ,Product Monograph ,Cell Based Flu ,Influenza Vaccine Stockpile ,Population Serologic Immunity ,Pandemic Risk ,Key Facts ,Estimated Influenza Illnesses ,Disease Control ,Who Needs ,Flu Vaccine ,Accessed September ,Pandemic Influenza Risk Management ,Seqirus ,